Sidera

CaMaRa

This company identifies genetic targets to develop novel treatments for patients with cardiometabolic and renal diseases.

Marea Therapeutics

This biotechnology company develops medicines for cardiometabolic and cardioendocrine diseases using human genetic data for patients with unmet medical needs.

Scenic Biotech

This company develops disease-modifying small molecule therapeutics for patients with rare genetic and neurodegenerative disorders using its proprietary genetic modifier discovery platform.

Adrestia

This company develops precision medicines for rare and common genetic diseases by using a molecular biology platform to identify and rescue cellular imbalances.

Eternygen

This biopharmaceutical company develops small molecule inhibitors targeting metabolic diseases, such as fatty liver and diabetes, for patients needing novel medical treatments.

Sitryx Therapeutics

The company develops oral small molecule therapies to treat patients with autoimmune and inflammatory diseases by regulating immune cell metabolism.

NodThera

The company develops oral small molecule inhibitors for inflammatory diseases to treat patients with cardiovascular, neurological and metabolic conditions.

Metsera

The company develops injectable and oral medicines for patients with obesity and metabolic diseases.